Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial by Wang, Eunice S, Prof, Issa, Ghayas C, MD, Erba, Harry P, Prof, Altman, Jessica K, Prof, Montesinos, Pau, MD, DeBotton, Stephane, MD, Walter, Roland B, Prof, Pettit, Kristen, MD, Savona, Michael R, Prof, Shah, Mithun Vinod, MD, Kremyanskaya, Marina, MD, Baer, Maria R, Prof, Foran, James M, Prof, Schiller, Gary, Prof, Adès, Lionel, Prof, Heiblig, Mael, MD, Berthon, Celine, MD, Peterlin, Pierre, MD, Rodríguez-Arbolí, Eduardo, MD, Salamero, Olga, MD, Patnaik, Mrinal M, Prof, Papayannidis, Cristina, MD, Grembecka, Jolanta, Prof, Cierpicki, Tomasz, Prof, Clegg, Bradley, BA, Ray, Joshua, BSc, Linhares, Brian M, PhD, Nie, Kun, PhD, Mitra, Amitava, PhD, Ahsan, Julie Mackey, MS, Tabachri, Marilyn, BSN, Soifer, Harris S, PhD, Corum, Daniel, PhD, Leoni, Mollie, MD, Dale, Stephen, MD, Fathi, Amir T, MD

Get full text